Interplay of m(6)A and histone modifications contributes to temozolomide resistance in glioblastoma

BACKGROUND: Despite the development of new treatment protocols for glioblastoma (GBM), temozolomide (TMZ) resistance remains a primary hindrance. Previous studies, including our study, have shown that aberrant N6‐methyladenosine (m(6)A) modification is implicated in GBM pathobiology. However, the ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fuxi, Chen, Siyun, Yu, Jiaming, Gao, Zhuoxing, Sun, Zhangyi, Yi, Yang, Long, Teng, Zhang, Chuanxia, Li, Yuzhe, Pan, Yimin, Qin, Chaoying, Long, Wenyong, Liu, Qing, Zhao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441140/
https://www.ncbi.nlm.nih.gov/pubmed/34586728
http://dx.doi.org/10.1002/ctm2.553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441140/
https://www.ncbi.nlm.nih.gov/pubmed/34586728
http://dx.doi.org/10.1002/ctm2.553

Ejemplares similares